ECSP034548A - Derivados de quinolinona como inhibidores de tirosin quinasa - Google Patents

Derivados de quinolinona como inhibidores de tirosin quinasa

Info

Publication number
ECSP034548A
ECSP034548A EC2003004548A ECSP034548A ECSP034548A EC SP034548 A ECSP034548 A EC SP034548A EC 2003004548 A EC2003004548 A EC 2003004548A EC SP034548 A ECSP034548 A EC SP034548A EC SP034548 A ECSP034548 A EC SP034548A
Authority
EC
Ecuador
Prior art keywords
inhibitors
tirosin
quinolinona
quinasa
derivatives
Prior art date
Application number
EC2003004548A
Other languages
English (en)
Inventor
Sabina Pecchi
Elisa Jazan
Paul Renhowe
Christopher Mcbride
Cynthia Shafer
Timothy D Machajewski
Clarke Taylor
Bill Mccrea
Alex Harris
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of ECSP034548A publication Critical patent/ECSP034548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención se refiere a un tratamiento de enfermedades caracterizadas por la actividad del factor de crecimiento vascular endotelial del receptor de tirosin quinasas. La presente invención provee, pequeñas moléculas inhibidoras del factor de crecimiento vascular endotelial del receptor de tirosin quinasa, formulaciones farmacéuticas que contienen dichos inhibidores, método de tratamiento en pacientes con dichas formulaciones farmacéuticas y los métodos de preparación de dichas formulaciones farmacéuticas e inhibidores.
EC2003004548A 2000-09-11 2003-04-08 Derivados de quinolinona como inhibidores de tirosin quinasa ECSP034548A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23215900P 2000-09-11 2000-09-11

Publications (1)

Publication Number Publication Date
ECSP034548A true ECSP034548A (es) 2003-05-26

Family

ID=22872101

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004548A ECSP034548A (es) 2000-09-11 2003-04-08 Derivados de quinolinona como inhibidores de tirosin quinasa

Country Status (34)

Country Link
US (6) US6605617B2 (es)
EP (3) EP1849782A1 (es)
JP (4) JP4361727B2 (es)
KR (3) KR100728797B1 (es)
CN (1) CN100351249C (es)
AP (1) AP1666A (es)
AT (2) ATE386736T1 (es)
AU (2) AU2001293275B2 (es)
BG (1) BG66087B1 (es)
BR (2) BRPI0113757B1 (es)
CA (1) CA2421120C (es)
CY (2) CY1108070T1 (es)
CZ (1) CZ304344B6 (es)
DE (2) DE60115069T2 (es)
DK (2) DK1317442T3 (es)
DZ (1) DZ3425A1 (es)
EA (1) EA006711B1 (es)
EC (1) ECSP034548A (es)
ES (2) ES2302106T3 (es)
HK (2) HK1053644A1 (es)
HU (1) HU230787B1 (es)
IL (3) IL154618A0 (es)
MA (1) MA27957A1 (es)
MX (1) MXPA03002032A (es)
NO (2) NO324155B1 (es)
NZ (1) NZ524717A (es)
OA (1) OA12428A (es)
PL (1) PL211125B1 (es)
PT (1) PT1650203E (es)
SG (2) SG129306A1 (es)
SK (1) SK287181B6 (es)
UA (1) UA75086C2 (es)
WO (1) WO2002022598A1 (es)
ZA (1) ZA200301578B (es)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
ES2302106T3 (es) * 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
US7622479B2 (en) 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US6921821B2 (en) * 2002-06-12 2005-07-26 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003275282A1 (en) * 2002-09-30 2004-04-23 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
EP1565187A4 (en) * 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
EP1590339A4 (en) * 2003-01-28 2007-07-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7627675B2 (en) * 2003-05-01 2009-12-01 Cisco Technology, Inc. Methods and devices for regulating traffic on a network
BRPI0412876A (pt) * 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
JP4724665B2 (ja) * 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
CN1878766B (zh) * 2003-11-07 2011-08-17 诺华疫苗和诊断公司 合成喹啉酮化合物的方法
US7767670B2 (en) * 2003-11-13 2010-08-03 Ambit Biosciences Corporation Substituted 3-carboxamido isoxazoles as kinase modulators
WO2005053692A1 (en) * 2003-12-01 2005-06-16 The Scripps Research Institute Advanced quinolinone based protein kinase inhibitors
CA2556872C (en) * 2004-02-20 2015-05-12 Chiron Corporation Modulation of inflammatory and metastatic processes
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
ES2374570T3 (es) * 2005-01-27 2012-02-17 Novartis Vaccines And Diagnostics, Inc. Tratamiento de tumores metastalizados.
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
MX2007014206A (es) * 2005-05-13 2008-02-07 Novartis Ag Metodos para tratar cancer resistente a los farmacos.
KR101324863B1 (ko) * 2005-05-17 2013-11-01 노파르티스 아게 헤테로고리 화합물의 합성 방법
KR101368519B1 (ko) 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
EP2614709A1 (en) 2005-07-18 2013-07-17 Novartis AG Small animal model for HCV replication
AU2006301292A1 (en) * 2005-10-14 2007-04-19 F. Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo (3, 4.-b) (1, 4) benzodiazepine
ES2420829T3 (es) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
DE102005054904A1 (de) * 2005-11-17 2007-05-24 Wacker Polymer Systems Gmbh & Co. Kg Verfahren zur Herstellung polyvinylalkoholstabilisierter Latices
CA2627544C (en) * 2005-11-29 2015-07-07 Novartis Ag Formulations of quinolinones for the treatment of cancer
EP1960547A2 (en) 2005-12-08 2008-08-27 Novartis AG Effects of inhibitors of fgfr3 on gene transcription
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EA015271B1 (ru) 2006-01-27 2011-06-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
TW200803855A (en) * 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
CA2647100A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
CA2646539A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
CA2648809A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of cdc7
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
WO2008006051A2 (en) 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
KR20090057015A (ko) 2006-09-11 2009-06-03 노파르티스 아게 난을 사용하지 않는 인플루엔자 바이러스 백신의 제조
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PT2137184E (pt) * 2007-04-03 2013-08-01 Array Biopharma Inc Compostos imidazo[1,2-a]piridina como inibidores do receptor de tirosina quinase
WO2008139288A2 (en) * 2007-05-09 2008-11-20 Pfizer Inc. Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
PL2185191T3 (pl) 2007-06-27 2013-02-28 Novartis Ag Szczepionki przeciwko grypie o małej zawartości dodatków
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
US8492374B2 (en) 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
AR078411A1 (es) 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
MX2012000734A (es) 2009-07-16 2012-01-27 Novartis Ag Inmunogenos destoxificados de escherichia coli.
WO2011033588A1 (ja) * 2009-09-18 2011-03-24 株式会社アドバンテスト 試験装置および試験方法
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US20120258940A1 (en) 2009-12-18 2012-10-11 Giordano Caponigro Method for treating haematological cancers
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
PT2558095T (pt) 2010-04-16 2019-01-29 Novartis Ag Composto orgânico para utilização no tratamento do cancro hepático
CA2795089A1 (en) 2010-04-16 2011-10-20 Novartis Ag Combination of organic compounds
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8859775B2 (en) 2010-09-02 2014-10-14 Merck Patent Gmbh Pyrazolopyridinone derivatives as LPA receptor antagonists
JO3062B1 (ar) 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
HUE043879T2 (hu) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa RSV-immunizálási rend
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
WO2012125812A1 (en) 2011-03-17 2012-09-20 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
DK3275892T3 (da) 2011-05-13 2020-04-06 Glaxosmithkline Biologicals Sa Præfusions-rsv-f-antigener
CN103547315A (zh) 2011-05-19 2014-01-29 诺华股份有限公司 用于治疗腺样囊性癌的4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
IN2014DN02060A (es) 2011-09-15 2015-05-15 Novartis Ag
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2771342B1 (en) 2011-10-28 2016-05-18 Novartis AG Purine derivatives and their use in the treatment of disease
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
CN104093402A (zh) 2012-01-31 2014-10-08 诺华股份有限公司 Rtk抑制剂与抗***的组合及其治疗癌症的应用
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
IN2014DN10801A (es) 2012-07-11 2015-09-04 Novartis Ag
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
CN103804353A (zh) * 2012-11-01 2014-05-21 常辉 一类治疗精神***症的化合物及其用途
RS56886B1 (sr) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Antigeni pseudomonasa i kombinacije antigena
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US20160095842A1 (en) 2013-05-31 2016-04-07 Christine Fritsch Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
AU2014334554B2 (en) 2013-10-14 2018-12-06 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
PL3076969T3 (pl) 2013-12-06 2022-01-17 Novartis Ag Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
BR112017000464A2 (pt) 2014-07-09 2017-11-07 Tc Biopharm Ltd células gama delta t e uso das mesmas
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
KR101693781B1 (ko) * 2014-10-06 2017-01-09 한양대학교 에리카산학협력단 다이플루오로알킬기가 도입된 방향족 화합물의 제조 방법
CN104817535A (zh) * 2015-03-19 2015-08-05 广西师范大学 一种喹啉酮衍生物及其合成方法及应用
CN104725431B (zh) * 2015-03-19 2017-05-17 广西师范大学 喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用
CN104774221B (zh) * 2015-03-19 2017-02-08 广西师范大学 喹啉酮衍生物的金属配合物及其合成方法及应用
JP6898306B2 (ja) 2015-08-07 2021-07-07 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
TW201711999A (zh) 2015-09-03 2017-04-01 佛瑪治療公司 ﹝６，６﹞稠合雙環組蛋白脫乙醯基酶８（ｈｄａｃ８）抑制劑
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
CA3002954A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
EP3231434A1 (en) 2016-04-14 2017-10-18 Fundacio Centre de Regulacio Genomica Method of treatment of parkinsonism
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CN107935858B (zh) * 2016-10-12 2020-09-08 利尔化学股份有限公司 5-氟-2-硝基苯酚的制备方法
EP3645526A4 (en) 2017-06-27 2020-10-28 Janssen Pharmaceutica NV NEW QUINOLEINONE COMPOUNDS
AU2018370904B2 (en) 2017-11-24 2023-09-21 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds
CN111655690B (zh) 2017-11-24 2023-01-10 詹森药业有限公司 吡唑并吡啶酮化合物
CN111448185A (zh) 2017-12-07 2020-07-24 哈尔滨珍宝制药有限公司 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法
CN109553534A (zh) * 2018-11-27 2019-04-02 常州大学 一种2-硝基-4-甲氧基苯甲酸的制备方法
US10835531B1 (en) 2019-06-18 2020-11-17 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158224A (en) * 1874-12-29 Improvement in eye-cups
DE236459C (es)
US207883A (en) * 1878-09-10 Improvement in drafting-pencils
US3663606A (en) 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
DE3248043A1 (de) 1982-12-24 1984-06-28 Bayer Ag, 5090 Leverkusen Fluorogene phosphorsaeureester, verfahren zu deren herstellung sowie verfahren und mittel zum nachweis und zur fluorometrischen bestimmung von phosphaten
US4659657A (en) 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
DE3634066A1 (de) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH07121937B2 (ja) * 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) * 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
CA1300918C (en) * 1987-06-12 1992-05-19 Masataka Kamitani Cement tile reinforced with fibers and a method for the production of the same
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
AU5881394A (en) 1994-01-08 1995-08-01 Rhone-Poulenc Agriculture Limited Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
BR9711805A (pt) 1996-06-20 2002-01-15 Regents The Univesity Of Texas Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
JP2001500890A (ja) * 1996-09-25 2001-01-23 ゼネカ リミテッド Ｖｅｇｆのような成長因子の作用を阻害するキノリン誘導体
US6111110A (en) 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
JP4209472B2 (ja) 1997-06-02 2009-01-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 平滑筋細胞増殖のインヒビターとしての（イミダゾール−５−イル）メチル−２−キノリノン誘導体
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
PL343112A1 (en) 1998-03-31 2001-07-30 Warner Lambert Co Quinolones as serine protease inhibitors
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
CA2333647A1 (en) 1998-06-29 2000-01-06 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
US6174912B1 (en) 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
AU1099000A (en) * 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
US20030087854A1 (en) 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
KR100373203B1 (ko) * 1999-03-31 2003-02-25 주식회사 엘지화학 새로운 큐마린계 착물 및 이를 이용한 유기 발광 소자
ES2328269T3 (es) 1999-05-21 2009-11-11 Bristol-Myers Squibb Company Pirrolotriazinas como inhibires de quinasas.
JP2003171280A (ja) 1999-06-07 2003-06-17 Fujisawa Pharmaceut Co Ltd 抗腫瘍効果増強剤
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
KR100298572B1 (ko) 1999-08-19 2001-09-22 박찬구 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
TR200201051T2 (tr) 1999-10-19 2002-09-23 Merck & Co., Inc. Tirosin kinaz inhibitörleri.
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7045133B2 (en) 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
CN101053573A (zh) 2000-01-19 2007-10-17 帕卡什·S·吉尔 针对反义vegf寡核苷酸的方法和组合物
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001062252A1 (en) 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001074296A2 (en) 2000-03-31 2001-10-11 Imclone Systems Incorporated Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
EP1351946A2 (en) 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
ES2334641T3 (es) * 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
EP1330441A2 (en) 2000-09-26 2003-07-30 The University of Arizona Foundation Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
AU2687702A (en) 2000-10-17 2002-04-29 Merck & Co Inc Orally active salts with tyrosine kinase activity
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
WO2003033472A1 (fr) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
AU2003275282A1 (en) 2002-09-30 2004-04-23 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
EP1565187A4 (en) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
EP1581539A4 (en) 2003-01-03 2007-09-19 Bristol Myers Squibb Co NEW TYROSINE KINASE HEMMER
DE60336931D1 (de) 2003-01-09 2011-06-09 Univ Delhi Verfahren zur synthese der bisbenzimidazolen und ihren derivaten.
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US6774327B1 (en) 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
JP4724665B2 (ja) 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
WO2005053692A1 (en) 2003-12-01 2005-06-16 The Scripps Research Institute Advanced quinolinone based protein kinase inhibitors

Also Published As

Publication number Publication date
KR20060101559A (ko) 2006-09-25
HK1064368A1 (en) 2005-01-28
US20040097545A1 (en) 2004-05-20
DE60132937T2 (de) 2009-02-12
JP2013100340A (ja) 2013-05-23
PL211125B1 (pl) 2012-04-30
US20020107392A1 (en) 2002-08-08
DE60132937D1 (de) 2008-04-03
US20050054672A1 (en) 2005-03-10
US6800760B2 (en) 2004-10-05
KR20030029974A (ko) 2003-04-16
JP2014129378A (ja) 2014-07-10
JP5649672B2 (ja) 2015-01-07
JP2004509112A (ja) 2004-03-25
AP1666A (en) 2006-09-29
DK1650203T3 (da) 2008-06-02
CA2421120A1 (en) 2002-03-21
HUP0301045A2 (hu) 2003-12-29
DZ3425A1 (fr) 2002-03-21
ZA200301578B (en) 2004-08-26
OA12428A (en) 2006-04-19
SG129306A1 (en) 2007-02-26
ATE309996T1 (de) 2005-12-15
SK2722003A3 (en) 2003-11-04
ES2250480T3 (es) 2006-04-16
EA006711B1 (ru) 2006-02-24
KR100765841B1 (ko) 2007-10-10
US7335774B2 (en) 2008-02-26
SG174632A1 (en) 2011-10-28
ES2302106T3 (es) 2008-07-01
BRPI0113757B1 (pt) 2017-05-23
MXPA03002032A (es) 2003-07-24
DE60115069T2 (de) 2006-08-03
KR100732206B1 (ko) 2007-06-27
US7598268B2 (en) 2009-10-06
CA2421120C (en) 2008-07-15
EP1650203A1 (en) 2006-04-26
KR100728797B1 (ko) 2007-06-19
PT1650203E (pt) 2008-05-13
AP2003002781A0 (en) 2003-06-30
EP1317442B1 (en) 2005-11-16
IL154618A0 (en) 2003-09-17
US6762194B2 (en) 2004-07-13
BG66087B1 (bg) 2011-03-31
US20030158224A1 (en) 2003-08-21
UA75086C2 (en) 2006-03-15
NO20071888L (no) 2003-03-25
NZ524717A (en) 2004-09-24
NO324155B1 (no) 2007-09-03
US20050209456A1 (en) 2005-09-22
EP1849782A1 (en) 2007-10-31
CY1108070T1 (el) 2014-02-12
IL200606A (en) 2010-12-30
HU230787B1 (en) 2018-05-02
EA200300354A1 (ru) 2003-10-30
CZ304344B6 (cs) 2014-03-19
US6774237B2 (en) 2004-08-10
DE60115069D1 (en) 2005-12-22
SK287181B6 (sk) 2010-02-08
AU2001293275B2 (en) 2005-04-14
IL154618A (en) 2010-04-29
JP2007191486A (ja) 2007-08-02
CN1483028A (zh) 2004-03-17
WO2002022598A1 (en) 2002-03-21
DK1317442T3 (da) 2006-02-13
BRPI0113757B8 (pt) 2017-11-07
NO328723B1 (no) 2010-05-03
KR20060036494A (ko) 2006-04-28
WO2002022598A8 (en) 2002-11-21
BG107709A (bg) 2004-01-30
EP1650203B1 (en) 2008-02-20
CZ2003683A3 (cs) 2003-08-13
ATE386736T1 (de) 2008-03-15
BR0113757A (pt) 2004-03-02
JP4361727B2 (ja) 2009-11-11
EP1317442A1 (en) 2003-06-11
MA27957A1 (fr) 2006-07-03
US6605617B2 (en) 2003-08-12
AU9327501A (en) 2002-03-26
NO20031097L (no) 2003-03-25
CN100351249C (zh) 2007-11-28
HK1053644A1 (en) 2003-10-31
CY1108931T1 (el) 2014-07-02
NO20031097D0 (no) 2003-03-10
PL361698A1 (en) 2004-10-04
US20040006101A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
ECSP034548A (es) Derivados de quinolinona como inhibidores de tirosin quinasa
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
DK1438052T3 (da) Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
NO20100777L (no) Kinazolinoner, slike forbindelser for anvendelse som medikament, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
ATE329596T1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
NO20092529L (no) Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
HUP0301749A2 (hu) Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ECSP066411A (es) Tienopirazoles
UY29186A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.